Beyond the direct psychedelic referenda in Massachusetts and some locales in Oregon, the reconstitution of the federal political landscape after tomorrow’s U.S. elections could also
I am a practicing psychiatrist, medical director, and assistant professor in psychiatry in Massachusetts. I also hold a PhD in the history of psychiatry, making
In this Issue VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control A Look at the Latest Oregon Psilocybin Services Complaints
The double-blind, multi-site randomised controlled trial will evaluate psilocybin’s potential in reducing opioid cravings and improving emotional well-being in individuals struggling with OUD but who
But even more substantial is the modified guidance for the company’s second readout, which Compass recently said was on track for a mid-2025 readout but
The article, Ballot Question 4 to Legalize Psychedelics Draws National Attention – and Dollars, was written by a trio of staff writers at the student
In this Issue Lykos’ Path to FDA Approval Might Include a Third-Party Review of Phase 3 Data, VA Funding of Phase 3 ‘Definitely a Possibility’
Full Natural Medicine Advisory Board: August During brief opening updates, DORA Program Director Lorey Bratten shared that as of the meeting, eight facilitator training programs
Later on in Tuesday’s debate, another misleading claim by Ghaemi caught the ire of longtime Boston Public Radio Co-host Jim Braude, who elicited a smattering
Earlier this week, shares in Bright Minds Biosciences (ticker DRUG) rocketed up more than 2,000% and, despite a slight correction over the past two days, are still